中华器官移植杂志
中華器官移植雜誌
중화기관이식잡지
CHINESE JOURNAL OF ORGAN TRANSPLANTATION
2014年
6期
333-336
,共4页
癌%肝细胞%肝移植%KLF4%预后
癌%肝細胞%肝移植%KLF4%預後
암%간세포%간이식%KLF4%예후
Carcinoma,hepatocellular%Liver transplantation%KLF4%Prognosis
目的 探讨转录因子Krüppel样因子4(KLF4)作为分子标志物联合米兰标准预测肝癌患者肝移植预后的价值.方法 回顾性分析2001年至2009年间接受肝移植的105例肝细胞肝癌患者的病例资料,应用免疫组织化学、蛋白质印迹等方法检测肝癌及癌旁组织中KLF4的表达,采用Kaplan-Meier法分析各组受者术后5年的总体存活率和无瘤存活率.结果 肝癌组织中KLF4蛋白表达低于相配对的癌旁组织(P＜0.05);在低分化肝癌组织中KLF4的表达显著低于中/高分化的肝癌组织(P=0.008),KLF4低表达是肝移植术后受者存活和肝癌复发的独立危险因素(相对危险度分别为4.59和5.42,P＜0.001).符合米兰标准的受者中,KLF4高表达的受者与低表达的受者间的总存活率及无瘤存活率均无显著差异(P＞0.05),但超出米兰标准的受者中,KLF4高表达的受者术后5年总体存活率和无瘤存活率分别达91.7％和70.5％,显著高于KLF4低表达的受者(P＜0.05).结论 KLF4是可用于肝癌患者肝移植预后分析的新的生物标志蛋白,检测肝癌组织KLF4蛋白的表达水平可以提高米兰标准预测肝癌患者肝移植术后存活率和肿瘤复发的准确度.
目的 探討轉錄因子Krüppel樣因子4(KLF4)作為分子標誌物聯閤米蘭標準預測肝癌患者肝移植預後的價值.方法 迴顧性分析2001年至2009年間接受肝移植的105例肝細胞肝癌患者的病例資料,應用免疫組織化學、蛋白質印跡等方法檢測肝癌及癌徬組織中KLF4的錶達,採用Kaplan-Meier法分析各組受者術後5年的總體存活率和無瘤存活率.結果 肝癌組織中KLF4蛋白錶達低于相配對的癌徬組織(P＜0.05);在低分化肝癌組織中KLF4的錶達顯著低于中/高分化的肝癌組織(P=0.008),KLF4低錶達是肝移植術後受者存活和肝癌複髮的獨立危險因素(相對危險度分彆為4.59和5.42,P＜0.001).符閤米蘭標準的受者中,KLF4高錶達的受者與低錶達的受者間的總存活率及無瘤存活率均無顯著差異(P＞0.05),但超齣米蘭標準的受者中,KLF4高錶達的受者術後5年總體存活率和無瘤存活率分彆達91.7％和70.5％,顯著高于KLF4低錶達的受者(P＜0.05).結論 KLF4是可用于肝癌患者肝移植預後分析的新的生物標誌蛋白,檢測肝癌組織KLF4蛋白的錶達水平可以提高米蘭標準預測肝癌患者肝移植術後存活率和腫瘤複髮的準確度.
목적 탐토전록인자Krüppel양인자4(KLF4)작위분자표지물연합미란표준예측간암환자간이식예후적개치.방법 회고성분석2001년지2009년간접수간이식적105례간세포간암환자적병례자료,응용면역조직화학、단백질인적등방법검측간암급암방조직중KLF4적표체,채용Kaplan-Meier법분석각조수자술후5년적총체존활솔화무류존활솔.결과 간암조직중KLF4단백표체저우상배대적암방조직(P＜0.05);재저분화간암조직중KLF4적표체현저저우중/고분화적간암조직(P=0.008),KLF4저표체시간이식술후수자존활화간암복발적독립위험인소(상대위험도분별위4.59화5.42,P＜0.001).부합미란표준적수자중,KLF4고표체적수자여저표체적수자간적총존활솔급무류존활솔균무현저차이(P＞0.05),단초출미란표준적수자중,KLF4고표체적수자술후5년총체존활솔화무류존활솔분별체91.7％화70.5％,현저고우KLF4저표체적수자(P＜0.05).결론 KLF4시가용우간암환자간이식예후분석적신적생물표지단백,검측간암조직KLF4단백적표체수평가이제고미란표준예측간암환자간이식술후존활솔화종류복발적준학도.
Objective To evaluate the prognostic value of combined analysis of the biomarker Krüppel-like factor 4 (KLF4) and the Milan criteria in hepatocellular carcinoma (HCC) patients treated by orthotopic liver transplantation (OLT).Method The clinicopathological data and outcome of the recruited 105 HCC patients undergoing OLT from October 2001 to April 2009 were retrospectively analyzed.KLF4 expression in HCC and paired non-tumor tissue was detected by immonohistochemistry and confirmed by Western blotting analysis.Five-year overall survival (OS) and recurrence-free survival (RFS) rate and survival curves of the grouped patients were calculated and plotted by Kaplan-Meier method.Result The level of KLF4 expression was lower in HCC than that in paired non-tumor tissue (P＜0.05).KLF4 expression was significantly lower in poorly differentiated HCC than that in well-moderately differentiated HCC (P =0.008).Loss of KLF4 was an independent risk factor for predicting tumor recurrence and survival of HCC after OLT (HR =0.459 and 5.42,respectively,P＜0.001).The level of KLF4 expression could not differentiate the OS and RFS rate in the patients with tumors meeting the Milan criteria,whereas the OS and RFS rate in the patients with tumors exceeding the Milan criteria differentiated according to KLF4 expression.The patients with tumors beyond the Milan criteria and exhibiting moderate to high KLF4 expression had unexpectedly favorable 5-year OS (91.7％) and RFS (70.5％) rate.Conclusion KLF4 is a useful biomarker for prognostication of HCC patients undergoing OLT.Integrated use of KLF4 biomarker and the Milan criteria improves accurate prediction of survival and tumor recurrence for HCC patients after OLT.
